Diminished ovarian reserve is the predominant risk factor for gonadotropin-releasing hormone antagonist failure resulting in breakthrough luteinizing hormone surges in in vitro fertilization cycles

Fertility and Sterility

Volumn 102, Issue 1, 2014, Pages 99-102

  Reichman, David E ^a   Zakarin, Lauren ^a   Chao, Kenny ^a   Meyer, Laura ^a   Davis, Owen K ^a   Rosenwaks, Zev ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

breakthrough ovulation; cancellation; GnRH antagonist; IVF; premature luteinization

Indexed keywords

ESTRADIOL; FOLLITROPIN; GONADORELIN ANTAGONIST; LUTEINIZING HORMONE;

ADULT; ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG TREATMENT FAILURE; FEMALE; FERTILIZATION IN VITRO; HUMAN; LUTEINIZING HORMONE RELEASE; MORNING DOSAGE; OUTCOME ASSESSMENT; OVARIAN RESERVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; TRANSVAGINAL ECHOGRAPHY;

BREAKTHROUGH OVULATION; CANCELLATION; GNRH ANTAGONIST; IVF; PREMATURE LUTEINIZATION;

ACADEMIC MEDICAL CENTERS; ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; ESTRADIOL; FEMALE; FERTILITY; FERTILITY AGENTS, FEMALE; FERTILIZATION IN VITRO; GONADOTROPIN-RELEASING HORMONE; HORMONE ANTAGONISTS; HUMANS; INFERTILITY; LUTEINIZING HORMONE; OVARY; PITUITARY GLAND; RISK FACTORS; TREATMENT FAILURE; UP-REGULATION;

EID: 84903379100     PISSN: 00150282     EISSN: 15565653     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2014.04.010     Document Type: Article

References (14)

1. G. Borm, and B. Mannaerts Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group Hum Reprod 15 2000 1490 1498
2. J. Itskovitz-Eldor, S. Kol, and B. Mannaerts Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report: short communication Hum Reprod 15 2000 1965 1968
3. M. Ludwig, R.E. Felberbaum, P. Devroey, C. Albano, H. Riethmuller-Winzen, and A. Schuler et al. Significant reduction of the incidence of ovarian hyperstimulation syndrome (OHSS) by using the LHRH antagonist Cetrorelix (Cetrotide) in controlled ovarian stimulation for assisted reproduction Arch Gynecol Obstet 264 2000 29 32
4. The ganirelix dose-finding study group A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). Hum Reprod 13 1998 3023 3031
5. M.H. Mochtar Dutch Ganirelix Study Group The effect of an individualized GnRH antagonist protocol on folliculogenesis in IVF/ICSI Hum Reprod 19 2004 1713 1718
6. H. Al-Inany, M.A. Aboulghar, R.T. Mansour, and G.I. Serour Optimizing GnRH antagonist administration: meta-Analysis of fixed versus flexible protocol Reprod Biomed Online 10 2005 567 570
7. E.M. Kolibianakis, C.A. Venetis, L. Kalogeropoulou, E. Papanikolaou, and B.C. Tarlatzis Fixed versus flexible gonadotropin-releasing hormone antagonist administration in in vitro fertilization: A randomized controlled trial Fertil Steril 95 2011 558 562
8. L. Vanrkrieken, F.A.L. Van der horst, and V.D. Castracane An international multicenter reference range study of normal menstrual cycles using IMMULITE reproductive hormone assays Clin Chem 45 Suppl 6 1999 A92
9. D.E. Reichman, P. Chung, L. Meyer, E. Greenwood, O. Davis, and Z. Rosenwaks Consecutive gonadotropin-releasing hormone-Antagonist in vitro fertilization cycles: does the elapsed time interval between successive treatments affect outcomes? Fertil Steril 99 2013 1277 1282
10. S. Dovey, K. McIntyre, D. Jacobson, J. Catov, and A. Wakim Is a premature rise in luteinizing hormone in the absence of increased progesterone levels detrimental to pregnancy outcome in GnRH antagonist in vitro fertilization cycles Fertil Steril 96 2011 585 589
11. N.E. Kummer, V.N. Weitzman, C.A. Benadiva, D.W. Schmidt, L.L. Engmann, and J.C. Nulsen In vitro fertilization outcomes in patients experiencing a premature rise in luteinizing hormone during a gonadotropin-releasing hormone antagonist cycle Fertil Steril 95 2011 2592 2594
12. I.E. Messinis, P. Vanakara, A. Zavos, C. Verikouki, P. Georgoulias, and K. Dafopoulos Failure of the GnRH antagonist ganirelix to block the positive feedback effect of exogenous estrogen in normal women Fertil Steril 94 2010 1554 1556
13. K. Dafopoulos, C.G. Kotsovassilis, S. Milingos, A. Kallitsaris, G. Galazios, and E. Zintzaras et al. Changes in pituitary sensitivity to GnRH in estrogen-treated post-menopausal women: evidence that gonadotrophin surge attenuating factor plays a physiological role Hum Reprod 19 2004 1985 1992
14. F. Martinez, P.N. Barri, B. Coroleu, R. Tur, T. Sorsa-Leslie, and W.J. Harris et al. Women with poor response to IVF have lowered circulating gonadotrophin surge-Attenuating factor (GnSAF) bioactivity during spontaneous and stimulated cycles Hum Reprod 17 2002 634 640